Increase In Approval of Biosimilar Drugs are Expected to Drive the Growth of The Behcet Disease Drug Market

The global Behcet disease drug market is anticipated to grow at a considerable CAGR during the forecast period. The use of biosimilars has increased in recent times. It will also rise in the future as biosimilars serve as a low-cost, easy option. Biosimilars are medicines that are close to biological drugs. They have the same characteristics, structure, and composition as biological drugs. Biologic drugs are those drugs that are made from several pieces of protein. Any brand drug has a parallel biosimilar to it. These biosimilars are safe and secure to consume when their efficacy is concerned. A drug that is of a particular brand also has its generic version. Generic drugs are clinically tested the same way as a biological drugs. It is expected that with time, biosimilar drugs would reduce the price of biological drugs. It all depends on how many biosimilar drugs are approved, tested, and become available for use in clinical purposes. 

Browse the full report description of “Global Behcet disease drug Market Size, Share & Trends Analysis Report by drug (Corticosteroid, Adalimumab Biosimilar, Infliximab Biosimilar, Apremilast, And Canakinumab) And By Route Of Administration (Oral, Intravenous, Intramuscular and Topical), Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/behcet-disease-drug-market

Biosimilars are used for treatment in Behcet or other inflammatory disease. For instance, in Oct 2021, FDA gives approval to Boehringer Ingelheim’s Cyltezo. This drug can be used as a substitute for Humira drugs. Humira drug is prescribed in various inflammatory conditions. Multiple biosimilars for Humira have been launched to date but no drug could make up to the market. Biosimilar drugs in the US have prices 15 to 35 percent lower than their reference products. There are 5 other biosimilars for Humira which will be launched at the end of 2023. 

Market Coverage

• The market number available for – 2021-2028

• Base year- 2021

• Forecast period- 2022-2028

• Segment Covered- 

o By Drug

o By route of administration

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Abbvie Inc., Celgene Corp., Cell Medica Ltd., Cohersu biosciences Inc., Genor biopharma Corp.Ltd. and others 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impact the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Behcet disease drug Market Report by Segment

By Drug

• Corticosteroid
• Adalimumab Biosimilar
• Infliximab Biosimilar
• Apremilast 
• Canakinumab 

By route of administration

• Oral
• Intravenous
• Intramuscular
• Topical

Global Behcet disease drug Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/behcet-disease-drug-market